WELCOME
Next-generation neuroscience for transformative treatments
INTRODUCTION
Psylo is a biotechnology company using innovative drug discovery approaches to develop next-generation treatments for psychiatric and neurological conditions that address unmet patient needs.
Our Approach
A NEW STARTING POINT
Emerging research suggests that the 5-HT2A serotonin receptor will unlock new therapeutic approaches to treat disease of the central nervous system. Compounds like psilocybin are showing great promise in treating mood disorders, addiction, and neurological conditions.
However, these medicines also face major scalability and accessibility challenges, including the need for specialized treatment providers, high costs, stigma, regulatory constraints, and strict exclusion criteria.
ACCESSIBLE SOLUTIONS
Psylo’s objective is to develop widely accessible, rapid-acting serotonergic agents without the side-effects and scalability challenges of psilocybin.
We achieve this by using our computationally-enhanced drug discovery platform to design and develop novel compounds with optimized pharmacological profiles.
Development Pipeline
Latest from Psylo
